ORAK HÜCRE HASTALIĞI
Anemi Tedavisi
Türkçe
Anemi Tedavisi
/assets/ct/579af9cf16/images/syn_placeholder_sqr.png

Orak Hücre Hastalığı

Anemi Tedavisi

A phase 1b/2 study of the efficacy and safety of combination hydroxyurea and dose-escalated erythropoietin for treatment of anemia in sickle cell disease (ACHiEvE-SCD). (yeni pencere açar)

Adeyemo TA, Kiriza N, Oluwole FT, Jelinek M, Jonassaint J, Oluwole O, Saber C, Philips BJ, Akinsanya OJD, Osunkalu VO, DeCastro LM, Novelli EM, Xu JZ

Kaynak‎: Blood 2024;144(Suppl 1):178-9.

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (yeni pencere açar)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Kaynak‎: Acta Haematol 1995;94(3):128-34.

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (yeni pencere açar)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Kaynak‎: Haematologica 2006;91(8):1076-83.

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (yeni pencere açar)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Kaynak‎: J Obstet Gynaecol 2007;27(1):82-3.